JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nanji, A. A.
Right arrow Articles by Lalani, E.-N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nanji, A. A.
Right arrow Articles by Lalani, E.-N.

Vol. 299, Issue 3, 832-839, December 2001

Arginine Reverses Ethanol-Induced Inflammatory and Fibrotic Changes in Liver Despite Continued Ethanol Administration

Amin A. Nanji, Kalle Jokelainen, George K. K. Lau, Amir Rahemtulla, George L. Tipoe, Rathnagiri Polavarapu and El-Nasir Lalani

Department of Pathology and Centre for The Study of Liver Diseases, University of Hong Kong and Queen Mary Hospital, Hong Kong (A.A.N.); Research Unit on Alcohol Diseases, Helsinki University Hospital, Helsinki, Finland (K.J.); Division of Gastroenterology and Hepatology, University of Hong Kong and Queen Mary Hospital, Hong Kong (G.K.K.L.); Department of Pathology, Harvard Medical School, Boston, Massachusetts (A.R.); Department of Anatomy, University of Hong Kong, Hong Kong (G.L.T.); DNA Sequencing Core Facility and Department of Biochemistry, Emory University School of Medicine, Atlanta, Georgia (R.P.); and Department of Histopathology, Hammersmith Hospital and Imperial College of Medicine, London, United Kingdom (E.-N.L.)

We investigated the potential of arginine to reverse pathological changes in alcohol-induced liver injury. Four groups (six rats/group) of male Wistar rats were fed a fish oil-ethanol diet for 6 (group 2) or 8 (group 1) weeks. Rats in group 3 were fed fish oil-ethanol for 6 weeks, after which they were administered arginine with fish oil-ethanol for an additional 2 weeks. Rats in group 4 were fed fish oil-dextrose for 8 weeks. Liver samples were analyzed for histopathology, lipid peroxidation, cytochrome P4502E1 activity, nuclear factor-kappa B, and levels of messenger RNA for tumor necrosis factor-alpha , cyclooxygenase-2, and inducible nitric oxide synthase. Concentrations of endotoxin were measured in plasma. The most severe inflammation and fibrosis was detected in groups 1 and 2, as were the highest levels of endotoxin, lipid peroxidation, cytochrome P450 2E1 activity, activation of nuclear factor-kappa B, and mRNA levels for tumor necrosis factor-alpha , cyclooxygenase-2, and inducible nitric oxide synthase. Plasma nitric oxide was also increased as was nitrotyrosine in liver. After arginine was administered, there was marked improvement in the pathological changes accompanied by decreased levels of endotoxin, lipid peroxidation, activation of nuclear factor-kappa B, tumor necrosis factor-alpha , cyclooxygenase-2, inducible nitric oxide, and nitrotyrosine staining. The therapeutic effects of arginine are probably secondary to increased levels of nitric oxide but other effects of arginine cannot be excluded.


0022-3565/01/2993-0832$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
Y. Lu, X. Wang, and A. I. Cederbaum
Lipopolysaccharide-induced liver injury in rats treated with the CYP2E1 inducer pyrazole
Am J Physiol Gastrointest Liver Physiol, August 1, 2005; 289(2): G308 - G319.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
P. Gong, A. I. Cederbaum, and N. Nieto
The Liver-Selective Nitric Oxide Donor O2-Vinyl 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (V-PYRRO/NO) Protects HepG2 Cells against Cytochrome P450 2E1-Dependent Toxicity
Mol. Pharmacol., January 1, 2004; 65(1): 130 - 138.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.